HK Stock Market Move | IMMUNEONCO-B (01541) rose more than 5% in intraday trading. Recently selling land and issuing shares to raise funds. CD47/SIRP fusion protein enters Phase III clinical trial.

IMMUNEONCO-B (01541) rose more than 5% during trading hours, up 3.19% as of the time of writing, at HK$5.18, with a turnover of HK$52.6684 million. In terms of news, Immuneonco has previously announced the sale of industrial land in the Kangqiao Industrial Park in Pudong New Area, Shanghai, with a land area of approximately 28,763 square meters to Zhangjiang Group for a maximum cash consideration of RMB 98.19 million. In addition, Immuneonco has recently completed a fundraising initiative, raising a net amount of approximately HK$230 million, with 70% of the funds allocated for key clinical research in China, including combination therapy with TPD-5ZP and TLRZ monoclonal antibodies; and about 30% for general corporate purposes. Pacific Securities pointed out that the company's CD47/SIRP fusion protein IMM01 in combination with TLRZ monoclonal antibody for the treatment of R/R cHL, and IMM01 in combination with azacytidine for the treatment of 1L CMML in phase III clinical trials are actively recruiting patients, with the potential to verify the drug properties of CD47/SIRP targets. In addition, the company's CD47/CD20 bispecific antibody IMM0306 in combination with lenalidomide for the treatment of B-NHL in phase Ib/IIa clinical trials, and IMM0306 for the treatment of SLE in phase Ib/II clinical trials are also actively recruiting patients. Furthermore, the company's PD-L1/VEGF bispecific antibody IMM2510 is currently undergoing early clinical trials in NSCLC, TNBC, and R/R STS indications.